GlassScriptPhysician profile
Celia Gutierrez
NPI 1861796609
$3,870.16
in general payments reported to CMS, 2019-2025
31 companies · $965 in 2025
The $965 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $601 · 2023: $857 · 2024: $1,065 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,887.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $569.73 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $445.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $360.27 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.18 | 2021-2025 | Jardiance, Tradjenta |
| Abiomed | $279.29 | 2022-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $270.54 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $268.17 | 2021-2025 | Spravato |
| Abbvie INC. | $252.49 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $197.03 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $189.66 | 2021-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $112.65 | 2024 | Voquezna |
| Exact Sciences Corporation | $64.13 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $62.48 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $60.69 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $59.85 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58.80 | 2023 | |
| Novartis Pharmaceuticals Corporation | $32.18 | 2023 | |
| Hologic Sales and Service, LLC | $28.60 | 2025 | Aptima |
| Teleflex LLC | $27.80 | 2025 | Urolift |
| Exeltis, USA INC. | $27.79 | 2023 | Slynd |
| Otsuka America Pharmaceutical, INC. | $23.11 | 2021 | |
| Averitas Pharma INC. | $22.87 | 2023 | Qutenza |
| Sun Pharmaceutical Industries INC. | $22.23 | 2022 | |
| Mayne Pharma Commercial LLC | $21.95 | 2023 | |
| Daiichi Sankyo INC. | $20.01 | 2021 | |
| Edwards Lifesciences Corporation | $17.46 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $17.12 | 2024 | |
| Amgen INC. | $16.23 | 2025 | Otezla, Repatha |
| Kyowa Kirin, INC. | $16.17 | 2023 | |
| Boston Scientific Corporation | $15.52 | 2022 | |
| Eisai INC. | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celia Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.